NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生物工程的皮膚替代品的全球市場 (2020-2030年):市場預測 (各產品、用途、終端用戶、地區)、競爭環境、法律規章方案

Global Bioengineered Skin Substitutes Market: Focus on Product Type, Application, End User, 4 Regional Data, 12 Countries' Data, Competitive Landscape, Regulatory Scenario, Analysis and Forecast, 2020-2030

出版商 BIS Research Inc. 商品編碼 973548
出版日期 內容資訊 英文 210 Pages
商品交期: 最快1-2個工作天內
價格
生物工程的皮膚替代品的全球市場 (2020-2030年):市場預測 (各產品、用途、終端用戶、地區)、競爭環境、法律規章方案 Global Bioengineered Skin Substitutes Market: Focus on Product Type, Application, End User, 4 Regional Data, 12 Countries' Data, Competitive Landscape, Regulatory Scenario, Analysis and Forecast, 2020-2030
出版日期: 2020年12月01日內容資訊: 英文 210 Pages
簡介

全球生物工程的皮膚替代品的市場規模2030年成長到43億3000萬美元的規模。組織工程領域的創新,創傷生物學的技術進步,慢性創傷和燒燙傷的發生率增加,政府的資金投入等要素促進該市場的成長。

本報告提供全球生物工程的皮膚替代品的市場調查,市場定義和概要,市場成長的各種影響因素分析,相關法律,已上市產品,市場規模的變化、預測,產品、用途、終端用戶、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊彙整。

摘要整理

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 市場概要

  • 皮膚替代品:簡介
  • 生物工程的皮膚替代品
  • 組織工程的過程、時間軸
  • 皮膚替代品的分類、種類
  • 已上市產品
  • 今後趨勢、展開
  • 對象市場規模、成長可能性

第5章 市場動態

  • 概要
  • 影響分析
  • 市場成長的促進因素
  • 市場成長的阻礙因素
  • 市場機會

第6章 產業考察

  • 產業的演進
  • 相關法規
  • 創傷管理成本
  • 創傷護理產品的供應鏈

第7章 競爭情形

  • 概要
  • 主要的展開、策略
  • 市場佔有率分析
  • 成長佔有率分析(機會製圖)

第8章 市場分析、預測:各產品

  • 概要
  • 同種異體
  • 自體
  • 異種遺傳基因
  • 無細胞
  • 其他

第9章 市場分析、預測:各用途

  • 概要
  • 慢性創傷
    • 靜脈性下肢潰瘍
    • 糖尿病足部潰傷(DFU)
    • 褥瘡(PU)
    • 其他
  • 急性創傷
    • 外科、外傷性創傷
    • 燒燙傷

第10章 市場分析、預測:各終端用戶

  • 概要
  • 醫院
  • 專門診所
  • 創傷護理中心
  • 其他

第11章 市場分析、預測:各地區、主要國家

  • 概要
  • 北美
    • 概要
    • 美國
    • 加拿大
  • 歐洲
    • 概要
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 概要
    • 中國
    • 日本
    • 澳洲
    • 韓國
    • 印度
    • 其他
  • 其他地區

第12章 企業簡介

  • Boston Scientific Corporation
  • Smith & Nephew plc
  • AbbVie Inc.
  • Stryker Corporation
  • Anika Therapeutics, Inc.
  • Zimmer Biomet Holdings, Inc.
  • Vericel Corporation
  • Integra LifeSciences Corporation
  • Aroa Biosurgery Limited
  • Organogenesis Inc.
  • Molnlycke Health Care AB
  • AlloSource
  • Cook Biotech Incorporated
  • Promethean LifeSciences, Inc.
  • ACell, Inc.
目錄
Product Code: BHL1012SA

"Global Bioengineered Skin Substitutes Market to Reach $4.33 Billion by 2030."

Market Report Coverage - Bioengineered Skin Substitutes

Market Segmentation

  • By Product: Allogenic, Autologous, Xenogeneic, Acellular, and Others
  • By Application: Chronic Wounds and Acute Wounds
  • By End User: Hospitals, Specialty Clinics, Wound Care Centers, and Others

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
  • Asia-Pacific - China, Australia, Japan, India, South Korea, and Rest-of-Asia-Pacific
  • Rest-of-the-World

Growth Drivers

  • Increasing Prevalence of Diabetes and Diabetic Foot Ulcers
  • Rising Cases of Chronic Wounds and Burn Injuries
  • Increasing Funds/Aids by the Government for Research Purposes
  • Growing Prominence of Regenerative Medicine and Tissue Engineering Products
  • Increasing Obesity

Market Challenges

  • Biocompatibility Issues and Stringent Regulations
  • Limitations of Skin Substitutes
  • Expensive Treatment

Market Opportunities

  • Patient Awareness and Improved Lifestyle in Emerging Economics
  • Advancing Inclination Toward Acellular Skin Substitutes

Key Companies Profiled

Anika Therapeutics, Inc., AbbVie, Inc., Smith & Nephew plc, Integra LifeSciences Corporation, Boston Scientific Corporation, Organogenesis, Inc., Molnlycke Health Care AB, Vericel Corporation, Stryker Corporation, Zimmer Biomet, and Aroa Biosurgery, Cook Biotech Incorporated, Promethean LifeSciences, Inc., XCELLentis NV, and AlloSource

Key Questions Answered in this Report:

  • What is the importance of bioengineered skin substitutes, and what is their origin? What are the different bioengineered skin substitutes products available in the market, and what are their benefits?
  • What are the major technological advancements witnessed by the global bioengineered skin substitutes market since 2015, and what is the future scope of the market? What are the current key trends of the global bioengineered skin substitutes market, and how is the market evolving?
  • What was the market size of the global bioengineered skin substitutes market in 2019, and what is the market size anticipated to be in 2030? What is the expected growth rate of the global bioengineered skin substitutes market during the period between 2020 and 2030?
  • What is the market scenario and growth potential of different regions of the world, including North America, Europe, Asia-Pacific, and Rest-of-the-World?
  • What are the major drivers, challenges, and opportunities of the global bioengineered skin substitutes market?
  • What are the major key players of the global bioengineered skin substitutes market? How much market share did each of these players occupy in the market in 2019? Which companies are anticipated to be highly disruptive in the future, and why?
  • What is the regulatory scenario of the global bioengineered skin substitutes market? What are the initiatives implemented by different governmental bodies and guidelines put forward by them to regulate the commercialization of bioengineered skin substitutes products?
  • What is the supply chain associated with wound care, and what is the cost associated with it?
  • What are the key developmental strategies implemented by the key players of the global bioengineered skin substitutes market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
  • What is the current revenue contribution of the global bioengineered skin substitutes market (by product type), and how is it expected to evolve in the forecast period?
  • What is the current revenue contribution of the global bioengineered skin substitutes market (by application type), and how is it expected to evolve in the forecast period?
  • What is the current revenue contribution of the global bioengineered skin substitutes market (by end user), and how is it expected to evolve in the forecast period?
  • Which region is expected to contribute the highest sales in the global bioengineered skin substitutes market during the period between 2019 and 2030? What are the leading countries of different regions that contribute significantly toward the growth of the global bioengineered skin substitutes market?

Market Overview

Technological advancements in wound biologics coupled with innovations in the field of tissue engineering have led to the development of advanced wound healing options and strategies, including bioengineered skin substitutes. These products are being designed to treat a wide range of acute and chronic wounds that pose a serious healthcare threat globally. According to a study published in the International Society for Pharmacoeconomics and Outcomes Research's Value in Health Journal (January 2018), the economic costs associated with chronic wound management in the U.S. is pegged between $28.1 to $31.7 billion for 8.2 million affected patients. Hence, increasing incidence of chronic wounds, as well as rising cases of burns injuries, are actively promoting the growth of the global bioengineered skin substitutes market. Further, the factors contributing to the huge demand for skin substitutes are their emerging applications, superior property, and huge investment by government and federal agencies.

BIS healthcare experts have found the global bioengineered skin substitutes market as one of the markets with high attractiveness from the investors, promoting huge investment driving technological innovations. The purpose of this study is to gain a holistic view of the bioengineered skin substitutes market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the products, applications, and end users associated with the global bioengineered skin substitutes market across different regions. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global bioengineered skin substitutes market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

Within the research report, the market has been segmented into 'products', 'applications', 'end-user', and 'regions'. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The bioengineered skin substitutes market is currently at a blooming phase, with the presence of various juggernauts such as AbbVie, Inc., Integra LifeSciences Corporation, Smith & Nephew plc, and Stryker Corporation, and other medium and small-medium enterprises that are offering a wide range of bioengineered skin substitutes products in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.

Table of Contents

Executive Summary

1. Product Definition

  • 1.1. Inclusion and Exclusion

2. Scope of the Work

  • 2.1. Overview: Report Scope
  • 2.2. Segmentation of the Global Bioengineered Skin Substitutes Market
  • 2.3. Assumptions and Limitations
  • 2.4. Key Questions Answered in the Report
  • 2.5. Base Year and Forecast Period

3. Research Methodology

  • 3.1. Overview: Report Methodology
  • 3.2. Primary Data Sources
  • 3.3. Secondary Data Sources
  • 3.4. Market Estimation Model
  • 3.5. Criteria for Company Profiling

4. Market Overview

  • 4.1. Introduction to Skin Substitutes
  • 4.2. Bioengineered Skin Substitutes
  • 4.3. History and Timeline of Tissue Engineering
  • 4.4. Classification and Types of Skin Substitutes
  • 4.5. Key Products Commercially Available in the Market
  • 4.6. Future Trends and Developments
  • 4.7. Addressable Market Size and Growth Potential, $Million, 2019-2030

5. Market Dynamics

  • 5.1. Overview
  • 5.2. Impact Analysis
  • 5.3. Market Drivers
    • 5.3.1. Increasing Prevalence of Diabetes and Diabetic Foot Ulcers
    • 5.3.2. Rising Cases of Chronic Wounds and Burn Injuries
    • 5.3.3. Increasing Funds/Aids by Governments for Research Purposes
    • 5.3.4. Growing Prominence of Regenerative Medicines and Tissue-Engineering Products
    • 5.3.5. Increasing Obesity
  • 5.4. Market Restraints
    • 5.4.1. Biocompatibility Issues and Stringent Regulations
    • 5.4.2. Limitations of Skin Substitutes
    • 5.4.3. Expensive Treatment
  • 5.5. Market Opportunities
    • 5.5.1. Patient Awareness and Improved Lifestyle in Emerging Economies
    • 5.5.2. Advancing Inclination Toward Acellular Skin Substitutes

6. Industry Insights

  • 6.1. Industry Evolution
  • 6.2. Regulatory Framework Monitoring Skin Substitutes
    • 6.2.1. Human-Derived Products Regulated Solely Under 21 CFR 1271 (HCT/Ps)
    • 6.2.2. Human and Human/Animal-Derived Products Regulated Through the Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Process
    • 6.2.3. Animal-Derived Products Regulated Under the 510(K) Process
    • 6.2.4. Biosynthetic Products Regulated Under the 510(K) Process
  • 6.3. Wound Management Cost
  • 6.4. Supply Chain of Wound Care Products

7. Competitive Landscape

  • 7.1. Overview
  • 7.2. Key Developments and Strategies
    • 7.2.1. M & A Activities
    • 7.2.2. Partnerships and Alliances
    • 7.2.3. Business Expansion
    • 7.2.4. Others
  • 7.3. Market Share Analysis
  • 7.4. Growth Share Analysis (Opportunity Mapping)
    • 7.4.1. By Product
    • 7.4.2. By Application

8. Global Bioengineered Skin Substitutes Market (by Product)

  • 8.1. Overview
  • 8.2. Allogenic
  • 8.3. Autologous
  • 8.4. Xenogeneic
  • 8.5. Acellular
  • 8.6. Other Products

9. Global Bioengineered Skin Substitutes Market (by Application)

  • 9.1. Overview
  • 9.2. Chronic Wounds
    • 9.2.1. Venous Leg Ulcers
    • 9.2.2. Diabetic Foot Ulcers (DFU)
    • 9.2.3. Pressure Ulcers (PUs)
    • 9.2.4. Other Chronic Wounds
  • 9.3. Acute Wounds
    • 9.3.1. Surgical and Traumatic Wounds
    • 9.3.2. Burn Injuries

10. Global Bioengineered Skin Substitutes Market (by End User)

  • 10.1. Overview
  • 10.2. Hospitals
  • 10.3. Specialty Clinics
  • 10.4. Wound Care Centers
  • 10.5. Others

11. Global Bioengineered Skin Substitutes Market (by Region)

  • 11.1. Overview
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. U.S.
    • 11.2.3. Canada
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Germany
    • 11.3.3. U.K.
    • 11.3.4. France
    • 11.3.5. Italy
    • 11.3.6. Spain
    • 11.3.7. Rest-of-Europe
  • 11.4. Asia-Pacific
    • 11.4.1. Overview
    • 11.4.2. China
    • 11.4.3. Japan
    • 11.4.4. Australia
    • 11.4.5. South Korea
    • 11.4.6. India
    • 11.4.7. Rest-of-Asia-Pacific
  • 11.5. Rest-of-the-Word

12. Company Profiles

  • 12.1. Overview
  • 12.2. Boston Scientific Corporation
    • 12.2.1. Company Overview
    • 12.2.2. Role of Boston Scientific Corporation in the Global Bioengineered Skin Substitutes Market
    • 12.2.3. Financials
    • 12.2.4. Key Insights About Financial Health of the Company
    • 12.2.5. SWOT Analysis
  • 12.3. Smith & Nephew plc
    • 12.3.1. Company Overview
    • 12.3.2. Role of Smith & Nephew plc in the Global Bioengineered Skin Substitutes Market
    • 12.3.3. Financials
    • 12.3.4. Key Insights About Financial Health of the Company
    • 12.3.5. SWOT Analysis
  • 12.4. AbbVie Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Role of AbbVie Inc. in the Global Bioengineered Skin Substitutes Market
    • 12.4.3. Financials
    • 12.4.4. Key Insights About Financial Health of the Company
    • 12.4.5. SWOT Analysis
  • 12.5. Stryker Corporation
    • 12.5.1. Company Overview
    • 12.5.2. Role of Stryker Corporation in the Global Bioengineered Skin Substitutes Market
    • 12.5.3. Financials
    • 12.5.4. SWOT Analysis
  • 12.6. Anika Therapeutics, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Role of Anika Therapeutics, Inc. in the Global Bioengineered Skin Substitutes Market
    • 12.6.3. Financials
    • 12.6.4. Key Insights About Financial Health of the Company
    • 12.6.5. SWOT Analysis
  • 12.7. Zimmer Biomet Holdings, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Role of Zimmer Biomet Holdings, Inc. in the Global Bioengineered Skin Substitutes Market
    • 12.7.3. Financials
    • 12.7.4. Key Insights About Financial Health of the Company
    • 12.7.5. SWOT Analysis
  • 12.8. Vericel Corporation
    • 12.8.1. Company Overview
    • 12.8.2. Role of Vericel Corporation in Global Bioengineered Skin Substitutes Market
    • 12.8.3. Financials
    • 12.8.4. Key Insights About Financial Health of the Company
    • 12.8.5. SWOT Analysis
  • 12.9. Integra LifeSciences Corporation
    • 12.9.1. Company Overview
    • 12.9.2. Role of Integra LifeSciences Corporation in the Global Bioengineered Skin Substitutes Market
    • 12.9.3. Financials
    • 12.9.4. Key Insights About Financial Health of the Company
    • 12.9.5. SWOT Analysis
  • 12.1. Aroa Biosurgery Limited
    • 12.10.1. Company Overview
    • 12.10.2. Role of Aroa Biosurgery Limited in the Global Bioengineered Skin Substitutes Market
    • 12.10.3. SWOT Analysis
  • 12.11. Organogenesis Inc.
    • 12.11.1. Company Overview
    • 12.11.2. Role of Organogenesis Holdings Inc. in the Global Bioengineered Skin Substitutes Market
    • 12.11.3. Financials
    • 12.11.4. Key Insights About Financial Health of the Company
    • 12.11.5. SWOT Analysis
  • 12.12. Molnlycke Health Care AB
    • 12.12.1. Company Overview
    • 12.12.2. Role of Molnlycke Health Care AB in the Global Bioengineered Skin Substitutes Market
    • 12.12.3. SWOT Analysis
  • 12.13. AlloSource
    • 12.13.1. Company Overview
    • 12.13.2. Role of AlloSource in the Bioengineered Skin Substitutes Market
    • 12.13.3. SWOT Analysis
  • 12.14. Cook Biotech Incorporated
    • 12.14.1. Company Overview
    • 12.14.2. Role of Cook Biotech Incorporated in the Bioengineered Skin Substitutes Market
    • 12.14.3. SWOT Analysis
  • 12.15. Promethean LifeSciences, Inc.
    • 12.15.1. Company Overview
    • 12.15.2. Role of Promethean LifeSciences, Inc. in the Bioengineered Skin Substitutes Market
    • 12.15.3. SWOT Analysis
  • 12.16. ACell, Inc.
    • 12.16.1. Company Overview
    • 12.16.2. Role of ACell, Inc. in the Bioengineered Skin Substitutes Market
    • 12.16.3. SWOT Analysis

List of Tables

  • Table 1: Leading Segments of the Global Bioengineered Skin Substitutes Market (by Revenue), 2019 and 2030
  • Table 4.1: Examples of Key Companies Offering Bioengineered Skin Substitutes
  • Table 5.1: Impact Analysis of Market Drivers
  • Table 5.2: Impact Analysis of Market Restraints
  • Table 5.3: Global Statistics of Diabetes and Diabetic Foot Ulcers
  • Table 5.4: Global Prevalence of Pressure Ulcer and Venous Leg Ulcer, 2018
  • Table 5.5: Examples of Acellular Skin Substitutes Offered by Key Companies
  • Table 6.1: Human-Derived Products Regulated Solely Under 21 CFR 1271 (HCT/Ps)
  • Table 6.2: Human and Human/Animal-Derived Products Regulated Through the Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Process
  • Table 6.3: Animal-Derived Products Regulated Under the 510(K) Process
  • Table 6.4: Biosynthetic Products Regulated Under the 510(K) Process
  • Table 7.1: M&A Activities (January 2017 and September 2020)
  • Table 7.2: Partnership and Alliances (January 2017 and September 2020)
  • Table 7.3: Business Expansions (January 2017 and September 2020)
  • Table 7.4: Other Key Developments (January 2017 and September 2020)
  • Table 8.1: Allogenic Products Offered by Key Companies
  • Table 8.2: Autologous Products Offered by Key Companies
  • Table 8.3: Xenogeneic Products Offered by Key Companies
  • Table 8.4: Acellular Products Offered by Key Companies
  • Table 9.1: Major Wound Types
  • Table 9.2: Global Venous Leg Ulcer Statistics
  • Table 9.3: Global Diabetic Foot Ulcer Statistics
  • Table 9.4: Global Pressure Ulcer Statistics

List of Figures

  • Figure 1: Global Bioengineered Skin Substitutes Market
  • Figure 2: Impact of Market Drivers and Market Restraints
  • Figure 3: Competitive Landscape (Key Developments: January 2017-September 2020)
  • Figure 4: Global Bioengineered Skin Substitutes Market Share (by Product), 2019 and 2030
  • Figure 5: Global Bioengineered Skin Substitutes Market Share (by Application), 2019 and 2030
  • Figure 6: Global Bioengineered Skin Substitutes Market Share (by End User), 2019 and 2030
  • Figure 7: Global Bioengineered Skin Substitutes Market Share (by Region), 2019 and 2030
  • Figure 2.1: Global Bioengineered Skin Substitutes Market Segmentation
  • Figure 3.1: Global Bioengineered Skin Substitutes Market Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.4: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 4.1: Common Characteristics of Ideal Skin Substitutes
  • Figure 4.2: Timeline of Skin Tissue Engineering in Burn Surgery
  • Figure 4.3: Different Classification of Skin Substitutes
  • Figure 4.4: Future Trends and Developments in Bioengineering/Tissue Engineering Market
  • Figure 4.5: Global Bioengineered Skin Substitutes Market (by Value)
  • Figure 5.1: Market Dynamics
  • Figure 5.2: Major Limitations of Skin Substitutes
  • Figure 6.1: Industry Trends in Advanced Wound Care Market
  • Figure 6.1: Cost Breakup, Wound Management Life Cycle
  • Figure 7.1: Competitive Landscape (January 2017- April 2020)
  • Figure 7.2: Share of Key Developments and Strategies, January 2017-June 2020
  • Figure 7.3: Market Share Analysis of Global Bioengineered Skin Substitutes Market, 2019
  • Figure 7.4: Growth Share Matrix for Global Bioengineered Skin Substitutes Market (by Product), 2019-2030
  • Figure 7.5: Growth Share Matrix for Global Bioengineered Skin Substitutes Market (by Application), 2019-2030
  • Figure 8.1: Global Bioengineered Skin Substitutes Market Segmentation (by Product)
  • Figure 8.2: Global Bioengineered Skin Substitutes Market (by Product), 2019-2030
  • Figure 8.3: Global Bioengineered Skin Substitutes Market (Allogenic Products), 2019-2030
  • Figure 8.4: Global Bioengineered Skin Substitutes Market (Autologous Products), 2019-2030
  • Figure 8.5: Global Bioengineered Skin Substitutes Market (Xenogeneic Products), 2019-2030
  • Figure 8.6: Global Bioengineered Skin Substitutes Market (Acellular Products), 2019-2030
  • Figure 8.7: Global Bioengineered Skin Substitutes Market (Other Products), 2019-2030
  • Figure 9.1: Global Bioengineered Skin Substitutes Market Segmentation (by Application)
  • Figure 9.2: Global Bioengineered Skin Substitutes Market (by Application), 2019-2030
  • Figure 9.3: Global Bioengineered Skin Substitutes Market (by Chronic Wound), 2019-2030
  • Figure 9.4: Global Bioengineered Skin Substitutes Market (by Chronic Wound Disease Type), 2019-2030
  • Figure 9.5: Global Bioengineered Skin Substitutes Market (Venous Leg Ulcers), 2019-2030
  • Figure 9.6: Global Bioengineered Skin Substitutes Market (Diabetic Foot Ulcers), 2019-2030
  • Figure 9.7: Global Bioengineered Skin Substitutes Market (Pressure Ulcers), 2019-2030
  • Figure 9.8: Global Bioengineered Skin Substitutes Market (Other Chronic Wounds), 2019-2030
  • Figure 9.9: Global Bioengineered Skin Substitutes Market (by Acute Wound), 2019-2030
  • Figure 9.10: Global Bioengineered Skin Substitutes Market (by Acute Wound), 2019-2030
  • Figure 9.11: Global Bioengineered Skin Substitutes Market ( Surgical and Traumatic Wounds), 2019-2030
  • Figure 9.12: Global Bioengineered Skin Substitutes Market (Burn Injury), 2019-2030
  • Figure 10.1: Global Bioengineered Skin Substitutes Market Segmentation (by End User)
  • Figure 10.2: Global Bioengineered Skin Substitutes Market (by End User), 2019-2030
  • Figure 10.3: Global Bioengineered Skin Substitutes Market (Hospitals), 2019-2030
  • Figure 10.4: Global Bioengineered Skin Substitutes Market (Specialty Clinic), 2019-2030
  • Figure 10.5: Global Bioengineered Skin Substitutes Market (Wound Care Centers), 2019-2030
  • Figure 10.6: Global Bioengineered Skin Substitutes Market (Others), 2019-2030
  • Figure 11.1: Global Bioengineered Skin Substitutes Market (by Region), 2019 and 2030
  • Figure 11.2: Global Bioengineered Skin Substitutes Market (by Region), 2019-2030
  • Figure 11.3: North America: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.4: North America: Market Dynamics
  • Figure 11.5: North America Bioengineered Skin Substitutes Market Share (by Country), 2019-2030
  • Figure 11.6: U.S. Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.7: Canada Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.8: Europe Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.9: Europe: Market Dynamics
  • Figure 11.10: Europe: Bioengineered Skin Substitutes Market Share (by Country), 2019-2030
  • Figure 11.11: Germany Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.12: U.K. Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.13: France: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.14: Italy: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.15: Spain: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.16: Rest-of-Europe: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.17: Asia-Pacific: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.18: Asia-Pacific: Market Dynamics
  • Figure 11.19: Asia-Pacific: Bioengineered Skin Substitutes Market Share (by Country), 2019-2030
  • Figure 11.20: China Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.21: Japan Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.22: Australia Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.23: South Korea Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.24: India Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.25: Rest-of-Asia-Pacific Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.26: Rest-of-the-World Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 12.1: Shares of Key Company Profiles
  • Figure 12.2: Boston Scientific Corporation: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.3: Boston Scientific Corporation: Overall Financials, 2017-2019
  • Figure 12.4: Boston Scientific Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.5: Boston Scientific Corporation: Revenue (by Region), 2017-2019
  • Figure 12.6: Boston Scientific Corporation: R&D Expenditure, 2017-2019
  • Figure 12.7: Boston Scientific Corporation: SWOT Analysis
  • Figure 12.8: Smith & Nephew plc: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.9: Smith & Nephew plc: Overall Financials, 2017-2019
  • Figure 12.10: Smith & Nephew plc: Revenue (by Segment), 2017-2019
  • Figure 12.11: Smith & Nephew plc: Revenue (by Region), 2017-2019
  • Figure 12.12: Smith & Nephew plc: R&D Expenditure, 2017-2019
  • Figure 12.13: Smith & Nephew plc: SWOT Analysis
  • Figure 12.14: AbbVie Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.15: AbbVie Inc.: Overall Financials, 2017-2019
  • Figure 12.16: AbbVie Inc.Revenue (by Region), 2017-2019
  • Figure 12.17: AbbVie Inc.: R&D Expenditure, 2017-2019
  • Figure 12.18: AbbVie Inc.: SWOT Analysis
  • Figure 12.19: Stryker Corporation: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.20: Stryker Corporation: Overall Financials, 2017-2019
  • Figure 12.21: Stryker Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.22: Stryker Corporation: Revenue (by Region), 2017-2019
  • Figure 12.23: Stryker Corporation: SWOT Analysis
  • Figure 12.24: Anika Therapeutics, Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.25: Anika Therapeutics, Inc.: Overall Financials, 2017-2019
  • Figure 12.26: Anika Therapeutics, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.27: Anika Therapeutics, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.28: Anika Therapeutics, Inc.: R&D Expenditure, 2017-2019

Figure12.29: Anika Therapeutics, Inc.: SWOT Analysis

  • Figure 12.30: Zimmer Biomet Holdings, Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.31: Zimmer Biomet Holdings, Inc.: Overall Financials, 2017-2019
  • Figure 12.32: Zimmer Biomet Holdings, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.33: Zimmer Biomet Holdings, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.34: Zimmer Biomet Holdings, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.35: Zimmer Biomet Holdings, Inc.: SWOT Analysis
  • Figure 12.36: Vericel Corporation: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12 37: Vericel Corporation: Overall Financials, 2017-2019
  • Figure 12.38: Vericel Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.39: Vericel Corporation: R&D Expenditure, 2017-2019
  • Figure 12.40: Vericel Corporation: SWOT Analysis
  • Figure 12.41: Integra LifeSciences Corporation: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.42: Integra LifeSciences Corporation: Overall Financials, 2017-2019
  • Figure 12.43: Integra LifeSciences Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.44: Integra LifeSciences Corporation: Revenue (by Region), 2017-2019
  • Figure 12.45: Integra LifeSciences Corporation: R&D Expenditure, 2017-2019
  • Figure 12.46: Integra LifeSciences Corporation: SWOT Analysis
  • Figure 12.47: Aroa Biosurgery Limited: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.48: Aroa Biosurgery Limited: SWOT Analysis
  • Figure 12.49: Organogenesis Holdings Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.50: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
  • Figure 12.51: Organogenesis Holdings Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.52: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
  • Figure 12.53: Organogenesis Holdings Inc.: SWOT Analysis
  • Figure 12.54: Molnlycke Health Care AB: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.55: Molnlycke Health Care AB: SWOT Analysis
  • Figure 12.56: AlloSource: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.57: AlloSource: SWOT Analysis
  • Figure 12.58: Cook Biotech Incorporated: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.59: Cook Biotech Incorporated: SWOT Analysis
  • Figure 12.60: Promethean LifeSciences, Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.61: Promethean LifeSciences, Inc.: SWOT Analysis
  • Figure 12.62: ACell, Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.63: ACell, Inc.: SWOT Analysis